Sage Journals: Discover world-class research

Abstract

Introduction: Hyperglycemia is a frequent sequela of critical illness. Rosiglitazone is an oral hypoglycemic agent of the thiazolinedione class. Thiazolinediones are known to activate peroxisome proliferator—activated receptor γ (PPAR-γ) that decreases inflammation in humans and decreases shock induced by zymosan in mice. Hypothesis: Rosiglitazone can assist with hyperglycemic control in the intensive care unit (ICU). Methods: A hospital billing query identified patients prescribed rosiglitazone while in a major university ICU. Patients who received rosiglitazone as an outpatient prior to hospitalization were excluded. Glycemic control was determined by average daily blood glucose, 24-hour insulin dose, and number of patients requiring an insulin drip. Glycemic control was evaluated on days 0, 3, and 7. Student t test was used to compare means. Fisher exact testing was used to compare insulin regimen before and after starting rosiglitazone. Results: 34 patients were identified. The average Acute Physiology and Chronic Health Evaluation (APACHE) II score was 17.2 ± 4.4. Sixty-five percent were male, 62% were preexisting diabetics. The mean daily blood glucose was 159 ± 30 mg/dL on day 0, 146 ± 37 mg/dL on day 3, and 140 ± 33 mg/dL on day 7 (P < .03 vs day 0). The mean 24-hour insulin dose was 80.6 ± 87.9 U on day 0, 72.2 ± 73.4 U on day 3, and 46.3 ± 57.2 U on day 7 (P < .003 vs day 0). There was 1 major hypoglycemic event. Conclusion: Rosiglitazone may assist glycemic control in the ICU. Despite recent concerns of cardiac safety, further research should be done to evaluate its potential as a short-term therapeutic agent in the ICU, given its anti-inflammatory and antishock profile.

Keywords

hyperglycemia critical illness hypoglycemic agents peroxisome proliferator—activated receptors

Get full access to this article

View all access options for this article.

References

Diaz-Delfin J. , Morales M. , Caelles C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes. 2007;56(7):1865-1871.

Krönke G. , Kadl A. , Ikonomu E. , et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors . Arterioscler Thromb Vasc Biol. 2007;27(6):1276-1282.

Yu X. , Li C. , Li X. , Cai L. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1. Toxicol Sci. 2007;96(2):346-356.

Cuzzocrea S. , Pisano B. , Dugo L. , et al. Rosiglitazone, a Ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eup J Pharm. 2004;483(1):79-93.

Bernard GR , Vincent JL , Laterre PF , et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. NEJM. 2001;344(10):699-709.

Krinsley J. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78(12):1471-1478.

Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 2006;105(2):244-252. 8. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Crit Care Med. 2008;36(11): 3008-30013.

Van den Berghe G. , Wouters P. , Weekers F. , et al. Intensive insulin therapy in the critically ill patient. N Engl J Med. 2001;345(19):1369-1367.

Krinsley JS Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79(8):992-1000.

10.

Brunkhorst FM , Engel C. , Bloos F. , et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. NEJM . 2008 ; 358(2):125-139.

11.

Wiener RS , Wiener DC , Larson RJ Benefits and risks of tight glucose control in critically ill adults . JAMA. 2008;300(8): 933-944.

12.

Dotson S. , Failing HJ , Freeman R. , Adler GK Hypoglycemia increases serum interleukin-6 levels in healthy men and women . Diabetes Care. 2008;31(6):1222-1223.

13.

Kidd LB , Schabbauer JP , Luyendyk JP , et al. Insulin activation of the phosphatidylinositol 3-kinase/protein kinase B (Akt) pathway reduces lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther. 2008;326(1):348-353.

14.

Mesotten D. , Swinnen JV , Vanderhoydonc F. , Wouters PJ , Van Den Berghe G. Contribution of circulating lipids to the improved outcome of critical illness by glycemic control with intensive insulin therapy. J Clin Endocinol Metab . 2004;89(1):219-226.

15.

Siroen MP , van Leeuwan PA , Nijveldt RJ , Teerlink T. , Woutyers PJ , Van Den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med. 2005;33(3):504-510.

16.

Brundage SI , Kirilcuk NN , Lam JC , Spain DA , Zautke NA Insulin increases the release of proinflammatory mediators. J Trauma. 2008;65(2):367-372.

17.

Vish MG , Mangeshkar P. , Piraino G. , et al. Proinsulin C-peptide exerts beneficial effects in endotoxic shock in mice. Crit Care Med. 2007;35(5):1348-1355.

18.

Kelly AS , Thelena AM , Kaiserb DR , Gonzalez-Campoycand JM , Bank AJ Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus . Vascular Medicine. 2007;12(4):311-318.

19.

Cuzzocrea S. , Pisano B. , Dugo L. , et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-, reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med . 2004;32(2):457-466.

20.

Liu D. , Zeng BX , Zhang SH , et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces acute lung injury in endotoxemic rats. Crit Care Med. 2005;33(10): 2309-2316.

21.

Chima RS , Hake PW , Piraino G. , Mangeshkar P. , Denenberg A. , Zingarelli B. Ciglitazone ameliorates lung inflammation by modulating the inhibitor κb protein/nuclear factor - κb pathway after hemorrhagic shock. Crit Care Med. 2008;36(10): 2849-2857.

22.

Chiquette E. , Ramirez G. , Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Int Med. 2004;164(19):2097-2104.

23.

Singh S. , Loke YK , Furberg CD Long-term risk of cardiovascular events with rosiglitazone. JAMA. 2007;298(10):1189-1195.

24.

Bhatt DL , Chew DP , Grines C. , et al. Peroxisome proliferator-activated receptor γ agonists for the prevention of adverse events following percutaneous coronary revascularization- results of the PPAR Study. Am Heart J. 2007 ;154(1):137-143.

25.

Dormandy JA , Charbonnel B. , Eckland DJA , et al. Secondary Prevention of Macrovascular Events in Patients with Type II Diabetes in the PROactive study (PROactive pioglitAzone clinical trial in macrovascular events): A Randomized Controlled Trial. Lancet. 2005 ;366(9493):1279-1289.

26.

Gerstein HC , Yusuf S. , Bosch J. , for the DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368(9541): 1096-1105.

27.

Home PD , Pocock SJ , Beck-Nielsen H. , et al, for the RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis . NEJM. 2007;357(1):1-11.

28.

Nesto RW , Bell D. , Bonow RO , et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108(23):2941-2948.

Rosiglitazone May Assist With Glycemic Control in the ICU

Abstract

Keywords

Get full access to this article

References